The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with resectable NSCLC.
Specifically, the immune checkpoint inhibitor — a programmed death receptor-1 blocking monoclonal antibody — has been approved for use in combination with platinum-doublet chemotherapy as neoadjuvant treatment, followed by adjuvant nivolumab monotherapy after surgery, in previously untreated adults with resectable stage IIA-IIIB disease and no known epidermal growth factor benefit with neoadjuvant nivolumab vs placebo with platinum-based chemotherapy followed by adjuvant single-agent nivolumab...
Patients were randomly assigned in a 1:1 ratio to the nivolumab or placebo arm. Neoadjuvant treatments were given every 3 weeks for up to four cycles, followed by adjuvant treatments every 4 weeks for up to 13 cycles.
Lung Carcinoma Cancer Of The Lung Non-Small Cell Lung Cancer Nsclc Neoadjuvant Chemotherapy Perioperative Surgery Anaplastic Lymphoma Kinase ALK ALK Tyrosine Kinase Receptor CD246 Cluster Of Differentiation 246 Leukemia Leukaemia Blood Cancer Small Cell Lung Cancer Small-Cell Lung Cancer Oat Cell Lung Cancer SCLC Biologic Therapy Biologics Cancer Malignant Neoplasia
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Exploratory Data Support Both Adjuvant and Neoadjuvant Nivolumab for NSCLCInvestigators analyzed patient-level data from the phase 3 CheckMate 77T and 816 trials.
Read more »
Breast cancer treatment: Drug Kisqali approval expanded for earlier stage diseaseMustafa Fattah is a medical fellow with the NBC News Health and Medical Unit.
Read more »
Nivolumab-Rucaparib Not Superior to Rucaparib as Maintenance Tx for Ovarian CancerThe efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.
Read more »
Osimertinib/Savolitinib Combo Shows Promise in NSCLCOsimertinib plus savolitinib demonstrated stronger efficacy than osimertinib alone in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC in the FLOWERS study.
Read more »
Perioperative Pembrolizumab Continues to Show Benefit in NSCLCThe event-free survival benefit with perioperative pembrolizumab in early NSCLC depends on the post-neoadjuvant residual tumor, suggested analysis.
Read more »
Aumolertinib Promising Maintenance Therapy in EGFR-Mutated NSCLCAumolertinib maintenance therapy led to a significant improvement in progression-free survival in unresectable, stage III, EGFR-mutated non–small cell lung cancer.
Read more »